Video

Dr. Chung on a Joint Analysis of Immunotherapy Trials in SCLC

Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).

Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).

In the phase Ib KEYNOTE-028 trial, investigators observed activity with pembrolizumab (Keytruda) monotherapy in patients with pretreated SCLC. However, it was unclear whether the benefit of the PD-1 inhibitor was restricted to patients with PD-L1 positivity, says Chung. As such, investigators looked to the KEYNOTE-158 trial, which examined the agent in patients irrespective of PD-L1 expression.

All patients in the joint analysis had received at least 2 prior lines of therapy for advanced disease. Of 131 patients enrolled in both trials, 83 were eligible for evaluation in the joint analysis. Data showed that approximately 10% of patients experienced durable responses with pembrolizumab monotherapy in the third-line, irrespective of PD-L1 status. Additional data indicated that the objective response rate was 19.3%, which included 2 complete responses and 14 partial responses.

Related Videos
John L. Marshall, MD
Petros Grivas, MD, PhD
Noopur S. Raje, MD
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
Atish D. Choudhury, MD, PhD
Benjamin Levy, MD
Paolo Tarantino, MD
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD